Skip to main content
. 2018 Feb 14;51(1):43–52. doi: 10.4143/crt.2017.562

Fig. 3.

Fig. 3.

The forest plots of progression-free survival in subgroups stratified by clinical factors. IX, irinotecan and capecitabine combination; X, capecitabine; HR, hazard ratio; CI, confidence interval; TNBC, triple negative breast cancer.